Tokyo, May 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061619) titled 'A study to evaluate the effects of obesity medications on kidney function in obese patients with chronic kidney disease' on May 18.
Study Type:
Observational
Primary Sponsor:
Institute - Kagawa University
Condition:
Condition - Obesity complicated with Chronic Kidney Disease (CKD)
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the changes in the urinary albumin-to-creatinine ratio (UACR) from baseline to 52 weeks after the initiation of GLP-1 or GLP-1/GIP receptor agonists, and to clarify their impact on renal microvascular damage in obese patients with chronic kidney disease (CKD).
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
= 30 mg/gCr, or an estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73m2, or both).
3.Age 18 years or older.
4.Individuals who have received an explanation about participating in this study and provided written consent.
Key exclusion criteria - Individuals falling under any of the following are excluded:
1.Pregnant or breastfeeding women.
2.Patients deemed inappropriate by the attending physician due to their medical condition, treatment status, or other reasons.
Target Size - 35
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2026 Year 01 Month 29 Day
Date of IRB - 2026 Year 02 Month 27 Day
Anticipated trial start date - 2026 Year 02 Month 27 Day
Last follow-up date - 2029 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070498
Disclaimer: Curated by HT Syndication.
